id110521156
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2023 (NCT06063291)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06635226 | Phase 1 | Oct 30, 2024 | IlDong Pharmaceutical Co Ltd |
| NCT06063291 | Phase 1 | Nov 15, 2023 | IlDong Pharmaceutical Co Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IlDong Pharmaceutical Co Ltd | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1